Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Other

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Adrenergic receptor beta

2

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Unknown

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

2

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

2

FDA UNII

2

PUBCHEM

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

1

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 2 of 2 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

CARTEOLOL, (S)-

0PE570TA5N

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Adrenergic receptor beta

Conditions:

(S)-Carteolol is an enantiomer of the racemic drug carteolol, that is used to treat glaucoma. (S) isomer is a partial agonist with the high affinity to the beta-adrenoceptors. It was shown, that in the treatment of glaucoma, the therapeutic advantage...

of the R(+)-isomers is similar to the S(-)-isomers and there is no stereo-selectivity between the two enantiomers.

CARTEOLOL HYDROCHLORIDE, (S)-

HJ5L26N5J9

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Adrenergic receptor beta

Conditions:

(S)-Carteolol is an enantiomer of the racemic drug carteolol, that is used to treat glaucoma. (S) isomer is a partial agonist with the high affinity to the beta-adrenoceptors. It was shown, that in the treatment of glaucoma, the therapeutic advantage...

of the R(+)-isomers is similar to the S(-)-isomers and there is no stereo-selectivity between the two enantiomers.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1